<DOC>
	<DOCNO>NCT01017939</DOCNO>
	<brief_summary>The purpose study evaluate effect multiple dos abiraterone acetate plus prednisone pharmacokinetics ( study body drug ) single dos dextromethorphan hydrobromide theophylline patient castration resistant prostate cancer .</brief_summary>
	<brief_title>A Drug-Drug Interaction Study Abiraterone Acetate Plus Prednisone With Dextromethorphan Theophylline Patients With Metastatic Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description>This open-label ( identity assign study drug know ) study abiraterone acetate plus prednisone male patient metastatic castration-resistant prostate cancer . This study consist screening , treatment , follow-up period , 2 study group . Patients Group A B receive daily abiraterone acetate ( 1000 mg ) plus prednisone ( 5 mg ) twice daily begin Cycle 1 Day 1 disease progression . Patients Group A take dextromethorphan hydrobromide 30 mg administer orally daily Day -8 Day 8 Cycle 1 . Patients Group B take theophylline 100 mg administer orally daily Day -8 Day 8 Cycle 1 . Serial pharmacokinetic sample collect safety monitor throughout study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<mesh_term>Dextromethorphan</mesh_term>
	<mesh_term>Theophylline</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma prostate without neuroendocrine differentiation small cell histology Documented metastatic disease Documented prostate specific antigen ( PSA ) progression accord Prostate Cancer Working Group 2 criterion , PSA value &gt; =2 ng/mL despite medical surgical castration , prostate cancer progression document radiographic progression accord Response Evaluation Criteria In Solid Tumors criterion Surgically medically castrate testosterone level &lt; 50 ng/dL Eastern Cooperative Oncology Group ( ECOG ) Performance Status &lt; =2 Group A : genomic test screen indicate CYP2D6 extensive metabolizer status Protocoldefined laboratory value Serious uncontrolled coexistent nonmalignant disease , include active uncontrolled infection Group A : genomic test screen indicate CYP2D6 nonextensive metabolizer status , prior treatment dextromethorphancontaining medication medication strong inhibitor inducer CYP2D6 within 5 halflives drug 7 day , whichever longer , prior Cycle 1 Day 8 Group B : prior treatment theophylline medication strong inhibitor inducer CYP1A2 within 5 halflives drug 7 day , whichever longer , prior Cycle 1 Day 8 Abnormal liver function Uncontrolled hypertension ( repeat systolic blood pressure &gt; =160 mmHg , diastolic blood pressure &gt; =95 mmHg ) Active symptomatic viral hepatitis chronic liver disease Known brain metastasis History pituitary adrenal dysfunction Clinically significant heart disease evidence myocardial infarction , arterial thrombotic event past 6 month , severe unstable angina , New York Heart Association Class III IV heart disease cardiac ejection fraction measurement &lt; 50 % baseline History gastrointestinal disorder ( medical disorder extensive surgery ) may interfere absorption study drug Surgery local prostatic intervention within 28 day first dose , clinically relevant sequela surgery must resolve prior Cycle 1 Day 1 Radiotherapy immunotherapy within 28 day , single fraction palliative radiotherapy within 14 day administration Cycle 1 Day 1 Any acute toxicity due prior therapy resolve Current enrollment investigational drug device study participation study within 28 day Cycle 1 Day 1 Previous abiraterone acetate investigational CYP17 inhibitor ( eg , TAK700 )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Prostate neoplasm</keyword>
	<keyword>Metastatic castration resistant prostate cancer</keyword>
	<keyword>Metastatic castration refractory prostate cancer</keyword>
	<keyword>Prostate cancer</keyword>
	<keyword>Abiraterone acetate</keyword>
	<keyword>CB7630</keyword>
</DOC>